TA
Tamarack Advisers Portfolio holdings
AUM
$2.12M
This Quarter Return
+0.68%
1 Year Return
-56.28%
3 Year Return
-45.76%
5 Year Return
+44.93%
10 Year Return
–
AUM
$131M
AUM Growth
+$131M
(-5.2%)
Cap. Flow
-$5.69M
Cap. Flow
% of AUM
-4.34%
Top 10 Holdings %
Top 10 Hldgs %
65.4%
Holding
45
New
8
Increased
11
Reduced
13
Closed
6
Top Buys
| 1 |
Amgen
AMGN
|
$7.25M |
| 2 |
Viatris
VTRS
|
$5.05M |
| 3 |
MDRX
Veradigm Inc. Common Stock
MDRX
|
$3.07M |
| 4 |
RadNet
RDNT
|
$2.79M |
| 5 |
Sanofi
SNY
|
$2.45M |
Top Sells
| 1 |
Alkermes
ALKS
|
$5.64M |
| 2 |
Biogen
BIIB
|
$5.54M |
| 3 |
Lantheus
LNTH
|
$5.35M |
| 4 |
Pacira BioSciences
PCRX
|
$3.67M |
| 5 |
Neogen
NEOG
|
$2.78M |
Sector Composition
| 1 | Healthcare | 99.96% |
| 2 | Consumer Staples | 0% |
| 3 | Technology | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Viatris
VTRS
$12.3B
| $14.4M | 5.27% |
1,500,000
+525,000
| +54% | +$5.05M |
|
|
MDRX
2
DELISTED
Veradigm Inc. Common Stock
MDRX
| $12.4M | 4.53% |
950,000
+235,000
| +33% | +$3.07M |
|
3
Phreesia
PHR
$1.88B
| $10.3M | 3.78% |
320,000
+35,000
| +12% | +$1.13M |
|
|
STRM
4
DELISTED
Streamline Health Solutions
STRM
| $8.88M | 3.24% |
4,930,882
| – | – |
|
5
Collegium Pharmaceutical
COLL
$1.22B
| $8.52M | 3.11% |
355,000
-32,000
| -8% | -$768K |
|
|
6
Amgen
AMGN
$155B
| $7.25M | 2.65% |
+30,000
| New | +$7.25M |
|
7
Cerus
CERS
$251M
| $6.68M | 2.44% |
2,250,000
-250,000
| -10% | -$743K |
|
8
Tenet Healthcare
THC
$16.3B
| $5.94M | 2.17% |
100,000
+5,000
| +5% | +$297K |
|
9
Tactile Systems Technology
TCMD
$297M
| $5.91M | 2.16% |
360,000
+105,000
| +41% | +$1.72M |
|
10
SI-BONE Inc
SIBN
$719M
| $5.41M | 1.98% |
275,000
-55,000
| -17% | -$1.08M |
|
|
11
RadNet
RDNT
$5.52B
| $5.29M | 1.93% |
211,500
+111,500
| +112% | +$2.79M |
|
12
DocGo
DCGO
$153M
| $5.28M | 1.93% |
610,000
+235,000
| +63% | +$2.03M |
|
|
13
Sanofi
SNY
$121B
| $5.17M | 1.89% |
95,000
+45,000
| +90% | +$2.45M |
|
14
AngioDynamics
ANGO
$417M
| $4.91M | 1.8% |
475,000
-15,000
| -3% | -$155K |
|
15
InMode
INMD
$944M
| $3.68M | 1.34% |
115,000
+25,000
| +28% | +$799K |
|
16
Rigel Pharmaceuticals
RIGL
$697M
| $2.64M | 0.96% |
2,000,000
-300,000
| -13% | -$396K |
|
17
Ironwood Pharmaceuticals
IRWD
$214M
| $2.21M | 0.81% |
210,000
+35,000
| +20% | +$368K |
|
18
Ascendis Pharma
ASND
$11.8B
| $2.14M | 0.78% |
20,000
-25,000
| -56% | -$2.68M |
|
|
19
Alkermes
ALKS
$4.78B
| $2.11M | 0.77% |
75,000
-200,000
| -73% | -$5.64M |
|
|
20
Neogen
NEOG
$1.25B
| $1.85M | 0.68% |
100,000
-150,000
| -60% | -$2.78M |
|
21
AtriCure
ATRC
$1.84B
| $1.67M | 0.61% |
40,376
-9,624
| -19% | -$399K |
|
22
United Therapeutics
UTHR
$13.8B
| $1.34M | 0.49% |
+6,000
| New | +$1.34M |
|
23
Fennec Pharmaceuticals
FENC
$247M
| $1.24M | 0.45% |
149,200
-63,800
| -30% | -$531K |
|
|
SLGC
24
DELISTED
SomaLogic, Inc. Class A Common Stock
SLGC
| $1.21M | 0.44% |
475,000
+225,000
| +90% | +$574K |
|
25
McKesson
MCK
$85.4B
| $1.07M | 0.39% |
+3,000
| New | +$1.07M |
|